Biomarkers for Predicting Neoadjuvant Chemoradio-resistance for Middle-low Advanced Rectal Cancer

Launched by WUHAN UNION HOSPITAL, CHINA · Jun 20, 2018

Keywords

ClinConnect Summary

This clinical trial is studying a type of cancer called rectal cancer, specifically how to predict which patients may not respond well to a treatment called neoadjuvant therapy. Neoadjuvant therapy is given before surgery to shrink tumors, but about half of the patients don’t see good results. Researchers want to find specific markers in the tumor that can help identify patients who are likely to resist this treatment. By doing this, they hope to help those patients go straight to surgery instead of undergoing an unnecessary treatment that may not work for them.

To be eligible for this trial, participants must have a confirmed diagnosis of rectal adenocarcinoma (a type of cancer), with the tumor located close to the anus. They should be at a specific stage of cancer (stages II-III) and have not received any prior cancer treatments like chemotherapy or radiation. Participants will be asked to agree to take part in the study and sign a consent form. If you or someone you know is interested, it’s a chance to contribute to important research that could improve treatment options for future patients with rectal cancer.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Histopathology proved to be adenocarcinoma of the rectum.
• • The edge of tumor is within 12cm of anus margin.
• • According to the eighth edition of AJCC TNM staging standard ,that staging for Ⅱ-Ⅲ period, as T3-T4, N0 or any T, N1-2.
• • There is no history of chemotherapy, radiotherapy or immunotherapy before neoadjuvant therapy.
• • Understand and agree to sign the informed consent for the study.
• Exclusion Criteria:
• • With intestinal obstruction or impending obstruction, or perforation.
• • With other malignancies occurred within 5 years.